Skip to main content
TheraSphere Y-90 Glass Microsphere glowing against blue background.

TheraSphere™ Y-90 Glass Microspheres

Control for durable outcomes

TheraSphere is a targeted radioembolization therapy made of glass microspheres containing radioactive Yttrium-90 (Y-90). Designed for control to achieve durable patient outcomes, TheraSphere preserves quality of life and provides reproducible results for treating and referring physicians. As the only FDA-approved Y-90 therapy for HCC, it is a cost-effective procedure backed by committed support from the industry leader, Boston Scientific.

Learn more about TheraSphere
Contact us

Durability leads to quality of life

Confidently destroy tumor cells with proven ablative dosing and a good patient safety profile.1

View clinical data
icon-person-with-medical-symbol.

Referring physicians

Cancer care is multidisciplinary. TheraSphere is a minimally invasive, well-tolerated interventional treatment for your patients with hepatocellular carcinoma. It provides proven tumor control with predictable outcomes that helps maintain patients' quality of life, while preserving future treatment options.² 

 

View referring physician information
icon-monitor-with-pointer.

Personalized dosing

Simplicit90Y™ is the only Y-90 personalized dosimetry software specifically designed for TheraSphere Y-90 Glass Microspheres. Simplicit90Y was developed to accelerate dosimetry planning and improve Y-90 Selective Internal Radiation Therapy (SIRT) workflow.

Learn more about TheraSphere dosing and Simplicit90Y
icon-truck

Get started with TheraSphere

Order TheraSphere using TheraSphere Now, a cloud-based website that facilitates personalized treatment order submission, tracking and order management. Increase treatment flexibility with expedited delivery of ready-to-deploy doses.

Order TheraSphere

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources

References

  1. LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  2. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y-90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x.

*Refers to HCC or associated tumors .

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.